In this episode, Banu Arun, MD; Allison Butts, PharmD, BCOP; and Marissa Marti-Smith, MSN, APRN, AGNP-C, AOCNP, discuss the role of BRCA testing and adjuvant olaparib in early breast cancer, including their experiences and challenges with implementing recent data. This overview will include discussion of: Data supporting the use of adjuvant PARP inhibition in early breast cancer and impact on BRCA testing and clinical practice The multidisciplinary role in ensuring that BRCA testing is completed for eligible patients Barriers to implementing BRCA testing and adjuvant olaparib in clinical practice and methods to overcome them Administration of adjuvant olaparib with other available adjuvant systemic therapiesTolerability of single-agent PARP inhibitors Presenters:Banu Arun, MDProfessor, Breast Medical Oncology Director, Clinical Cancer Genetics University of Texas MD Anderson Cancer Center Houston, Texas Allison Butts, PharmD, BCOPPharmacist Manager, Oncology Director, PGY2 Oncology Residency Program UK HealthCare Assistant Adjunct ProfessorUK College of Pharmacy Lexington, Kentucky Marissa Marti-Smith, MSN, APRN, AGNP-C, AOCNPNurse Practitioner Breast OncologyTexas Oncology Baylor Sammons Cancer Center Dallas, Texas Content supported by educational grants from AstraZeneca and Merck Sharp & Dohme Corp. Link to full program:https://bit.ly/42VeUMM

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related